Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Anthracycline | Correction

Correction to: Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer

Authors: Amy A. Kirkham, D. Ian Paterson, Carla M. Prado, John R. Mackey, Kerry S. Courneya, Edith Pituskin, Richard B. Thompson

Published in: BMC Cancer | Issue 1/2019

Login to get access

Excerpt

Correction to: BMC Cancer …
Literature
1.
Metadata
Title
Correction to: Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer
Authors
Amy A. Kirkham
D. Ian Paterson
Carla M. Prado
John R. Mackey
Kerry S. Courneya
Edith Pituskin
Richard B. Thompson
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Anthracycline
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5298-9

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

Outcomes and outcome measures used in evaluation of communication training in oncology – a systematic literature review, an expert workshop, and recommendations for future research

Research article

Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway

Research article

Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study

Research article

Intratumor heterogeneity index of breast carcinomas based on DNA methylation profiles

Research article

Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

Research article

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits